# US 5,702,882 A · Reagent for endotoxin-specific assay > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 5,702,882 A - Document ID: US5702882A - Status: Granted - Kind: A - Application number: 08/313,899 - Filed: 1994-09-28 - Granted: 1997-12-30 - Earliest claimed: 1993-09-30 - Assignees: Seikagaku Kogyo Kabushiki Kaisha (Seikagaku Corporation) - Inventors: Hiroshi Tamura; Toshio Oda; Shigenori Tanaka - Web page: https://patentgrep.com/patent/US5702882A ## CPC - G01N 33/579: involving limulus lysate - Y10S 435/975: Kit - G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q) - Y10S: TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS ## Abstract Endotoxin (Et) can be specifically assayed by exclusively utilizing the factor C system reaction without being affected by factor G contained in a limulus amebocyte lysate reagent. The present invention provides: (1) a reagent for ET-specific assay which comprises a limulus amebocyte lysate reagent and an alkylglucoside; (2) a method of specifically assaying Et in a specimen using a limulus amebocyte lysate reagent, wherein an alkylglucoside is added to the limulus amebocyte lysate reagent and/or the specimen; and (3) a factor G activation inhibitor composition which comprises an alkylglucoside as an active ingredient capable of inhibiting the activation of factor G in limulus amebocyte by (1.fwdarw.3)-.beta.-D-glucan. ## Claims ### Claim 1 A reagent for endotoxin-specific assay which comprises a limulus amebocyte lysate reagent and an alkylglucoside. ### Claim 2 (depends on 1) The reagent for endotoxin-specific assay according to claim 1, wherein said alkylglucoside is contained in an amount effective for inhibiting activation of factor G existing in said limulus amebocyte lysate reagent. ### Claim 3 (depends on 1) The reagent for endotoxin-specific assay according to claim 1, wherein an alkyl group contained in the alkylglucoside has from 1 to 30 carbon atoms. ### Claim 4 (depends on 1) The reagent for endotoxin-specific assay according to claim 1, wherein, in said alkylglucoside, glucose or glucose of a reducing end of a glucoside moiety is bound to an alkyl group via a glycosidic linkage. ### Claim 5 (depends on 4) The reagent for endotoxin-specific assay according to claim 4, wherein said alkylglucoside is an alkyl-O-.beta.-D-glucoside or an alkyl-S-.beta.-D-glucoside. ### Claim 6 (depends on 4) The reagent for endotoxin-specific assay according to claim 4, wherein said alkylglucoside is selected from the group consisting of n-octyl-.beta.-D-glucoside, n-heptyl-.beta.-D-glucoside, n-dodecyl-.beta.-D-glucoside, n-octyl-.beta.-D-thioglucoside and n-heptyl-.beta.-D-thioglucoside. ### Claim 7 (depends on 1) The reagent for endotoxin-specific assay according to claim 1, wherein said alkylglucoside is soluble or dispersible in water. ### Claim 8 A method of assaying for endotoxin in a specimen using a limulus amebocyte lysate reagent, comprising the steps of: (a) adding an alkylglucoside to the limulus amebocyte lysate reagent and/or the specimen, and (b) assaying for endotoxin in the specimen. ### Claim 9 (depends on 8) The method of specifically assaying endotoxin according to claim 8, wherein the alkylglucoside is added in an amount effective for inhibiting activation of factor G existing in the limulus amebocyte lysate reagent. ### Claim 10 (depends on 8) The method of specifically assaying endotoxin according to claim 8, wherein, in said alkylglucoside, glucose or glucose of a reducing end of a glucoside moiety is bound to an alkyl group via a glycosidic linkage. ### Claim 11 A kit for endotoxin-specific assay which comprises a limulus amebocyte lysate reagent and a reagent containing an alkylglucoside. ### Claim 12 (depends on 11) The kit according to claim 11, wherein said reagent containing alkylglucoside further contains a buffer agent. ### Claim 13 (depends on 11) The kit according to claim 11, which further comprises a reagent containing a substrate for clotting enzyme. ### Claim 14 (depends on 13) The kit according to claim 13, wherein said substrate is a coagulogen or a synthetic peptide substrate. ### Claim 15 (depends on 11) The kit for endotoxin-specific assay according to claim 11, wherein, in said alkylglucoside, glucose or glucose of a reducing end of a glucoside moiety is bound to an alkyl group via a glycosidic linkage. ### Claim 16 A factor G activation inhibitor composition which comprises an alkylglucoside as an active ingredient capable of inhibiting the activation of factor G existing in limulus amebocyte by (1.fwdarw.3)-.beta.-D-glucan and, water or a buffer agent free from endotoxin. ### Claim 17 (depends on 16) The factor G activation inhibitor composition according to claim 16, wherein, in said alkylglucoside, glucose or glucose of a reducing end of a glucoside moiety is bound to an alkyl group via a glycosidic linkage. ### Claim 18 A method for inhibiting activation of factor G existing in a limulus amebocyte lysate reagent comprising the step of adding an alkylglucoside to the limulus amebocyte lysate reagent. ### Claim 19 (depends on 18) The method for inhibiting activation of factor G according to claim 18, wherein, in said alkylglycoside, glucose or glucose of a reducing end of a glucoside moiety is bound to an alkyl group via a glycosidic linkage.